



## Bronchodilator reversibility testing in chronic obstructive pulmonary disease

P M A Calverley, P S Burge, S Spencer, J A Anderson and P W Jones

*Thorax* 2003;58;659-664  
doi:10.1136/thorax.58.8.659

---

Updated information and services can be found at:  
<http://thorax.bmj.com/cgi/content/full/58/8/659>

---

*These include:*

### References

This article cites 23 articles, 12 of which can be accessed free at:  
<http://thorax.bmj.com/cgi/content/full/58/8/659#BIBL>

29 online articles that cite this article can be accessed at:  
<http://thorax.bmj.com/cgi/content/full/58/8/659#otherarticles>

### Email alerting service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

---

### Topic collections

Articles on similar topics can be found in the following collections  
[Chronic Obstructive Airways Disease](#) ( articles)

---

### Notes

---

To order reprints of this article go to:  
<http://www.bmjournals.com/cgi/reprintform>

To subscribe to *Thorax* go to:  
<http://www.bmjournals.com/subscriptions/>

## CHRONIC OBSTRUCTIVE PULMONARY DISEASE

# Bronchodilator reversibility testing in chronic obstructive pulmonary disease

P M A Calverley, P S Burge, S Spencer, J A Anderson, P W Jones, for the ISOLDE Study Investigators

*Thorax* 2003;58:659–664

See end of article for authors' affiliations

Correspondence to:  
Professor P M A Calverley,  
Clinical Science Centre,  
University Hospital Aintree,  
Liverpool L9 7AL, UK;  
pmacal@liverpool.ac.uk

Revised version received  
16 January 2003  
Accepted for publication  
25 April 2003

**Background:** A limited or absent bronchodilator response is used to classify chronic obstructive pulmonary disease (COPD) and can determine the treatment offered. The reliability of the recommended response criteria and their relationship to disease progression has not been established.

**Methods:** 660 patients meeting European Respiratory Society (ERS) diagnostic criteria for irreversible COPD were studied. Spirometric parameters were measured on three occasions before and after salbutamol and ipratropium bromide sequentially or in combination over 2 months. Responses were classified using the American Thoracic Society/GOLD (ATS) and ERS criteria. Patients were followed for 3 years with post-bronchodilator FEV<sub>1</sub> and exacerbation history recorded 3 monthly and health status 6 monthly.

**Results:** FEV<sub>1</sub> increased significantly with each bronchodilator, a response that was normally distributed. Mean post-bronchodilator FEV<sub>1</sub> was reproducible between visits (intraclass correlation 0.93). The absolute change in FEV<sub>1</sub> was independent of the pre-bronchodilator value but the percentage change correlated with pre-bronchodilator FEV<sub>1</sub> ( $r=-0.44$ ;  $p<0.0001$ ). Using ATS criteria, 52.1% of patients changed responder status between visits compared with 38.2% using ERS criteria. Smoking status, atopy, and withdrawing inhaled corticosteroids were unrelated to bronchodilator response, as was the rate of decline in FEV<sub>1</sub>, decline in health status, and exacerbation rate.

**Conclusion:** In moderate to severe COPD bronchodilator responsiveness is a continuous variable. Classifying patients as "responders" and "non-responders" can be misleading and does not predict disease progression.

Chronic obstructive pulmonary disease (COPD) is currently defined by the presence of airflow limitation, measured by the forced expiratory volume in 1 second (FEV<sub>1</sub>), that shows little or no improvement after inhaled bronchodilator drugs.<sup>1–3</sup> Selection of the maximum change in FEV<sub>1</sub> compatible with a diagnosis of COPD has proved difficult, but could be important clinically. Approximately 10% of patients with COPD show a short term spirometric "response" to a course of oral corticosteroids<sup>4</sup> that is maintained during subsequent inhaled corticosteroid treatment.<sup>5</sup> This is most likely to occur in those patients with a substantial (>400 ml) improvement in FEV<sub>1</sub> after oral corticosteroids.<sup>6</sup> A positive bronchodilator response may define a different natural history,<sup>7,8</sup> while European regulators now require that COPD patients included in treatment trials meet the European Respiratory Society (ERS) definition of irreversible disease. Bronchodilator testing can therefore have both clinical and regulatory importance.

Several criteria have been proposed to define a significant bronchodilator response.<sup>9</sup> Each has tried to encompass the known variability in FEV<sub>1</sub> measurements between and within days<sup>10</sup> by including a threshold value to reduce the risk of a chance finding. However, the approaches adopted differ. The American Thoracic Society (ATS) and the Global initiative for Obstructive Lung Disease (GOLD) both use a change of >12% of the baseline if this also exceeds 200 ml,<sup>11,12</sup> while the ERS recommends a change that is >9% of the predicted FEV<sub>1</sub>.<sup>13</sup> Many reports simply quote a percentage change from baseline, which varies between 12 and 20%.<sup>14</sup> The reliability of these definitions has been challenged previously by data from the IPPB study<sup>15</sup> and in primary care where the patients studied had relatively mild disease and the stability of the categorisation was not assessed.<sup>9</sup> Direct comparisons between the different criteria and the effect of adding other bronchodilator

drugs on the subsequent response rate have not been reported in large numbers of stable patients with moderate to severe COPD. Other factors such as smoking status, atopy, or changes in treatment may also influence the likelihood of a response.<sup>16</sup>

To determine whether routine bronchodilator testing is a robust measurement in individual patients already classified as having "poorly reversible" COPD, we examined data from the pre-randomisation phase of the ISOLDE (Inhaled Steroids in Obstructive Lung Disease) study.<sup>17</sup> We hypothesised that the number of patients classified as reversible would be influenced by spontaneous variation in airway calibre and by the use of additional test drugs, regardless of the choice of threshold for reversibility. We also tested the effect of atopy, smoking status, or the withdrawal of inhaled corticosteroids on the response to inhaled bronchodilators. Finally, we tested the hypotheses that the size of the bronchodilator response predicted the subsequent rate of decline in FEV<sub>1</sub>, health status, or exacerbation rate over the following 3 years.

## METHODS

Patients were recruited from the outpatient clinics of 18 UK hospital centres. All had a clinical diagnosis and symptoms compatible with non-asthmatic COPD and met both the ERS and ATS<sup>1,2</sup> spirometric criteria for this disorder. All were aged 40–75 years and were current or ex-tobacco smokers. Their baseline post-salbutamol FEV<sub>1</sub> was at least 0.81 but <85% predicted and all had a ratio of FEV<sub>1</sub> to forced vital capacity (FVC) of <70%. At the first visit we excluded from further follow up those patients whose FEV<sub>1</sub> improved after inhaled salbutamol by more than 10% of their predicted FEV<sub>1</sub>. Other exclusion criteria included the use of  $\beta$  adrenergic blockers, regular oral corticosteroids, or co-morbidities likely to reduce life expectancy below 5 years. Nasal and ophthalmic

**Table 1** Demographic and lung function characteristics of study subjects

	N	Mean (SD)
Patients with complete data	660	
Pre-salbutamol FEV <sub>1</sub> (l)	660	1.28 (0.46)
Pre-salbutamol FEV <sub>1</sub> (% predicted)	660	45.5 (14.9)
Pre-salbutamol FVC (l)	660	2.94 (0.76)
Pre-salbutamol FEV <sub>1</sub> /FVC	660	0.43 (0.11)
TlCO (mmol/min/kPa)*	556	4.91 (2.10)
Age (years)	660	63.8 (7.0)
Pack years smoked	615	44.6 (32.4)
Current smokers/ex-smokers	314/345	48%/52%
M/F	497/163	75%/25%
Atopic/non-atopic	175/485	27%/73%
Previous use of regular inhaled steroids (yes/no)	353/307	53%/47%

FEV<sub>1</sub>=forced expiratory volume in 1 second; FVC=forced vital capacity; TlCO=carbon monoxide transfer factor.

\*Normal range 10.84 (2.52) mmol/min/kPa.

corticosteroids, theophyllines, other oral bronchodilators, and any inhaled bronchodilators were allowed. All patients gave their written informed consent before the study, which was approved by the local ethical committees of the participating institutions.

### Measurements


All spirometric measurements were made using identical rolling seal spirometers (Sensormedics 2130D, BV Warwickshire, UK). Forced expiratory manoeuvres were performed in a standardised fashion<sup>13</sup> and the best FEV<sub>1</sub> and FVC recordings within 50 ml of each other were accepted. We developed an intra-centre and inter-centre quality control protocol based on the criteria used in the Lung Health Study.<sup>18</sup> These were modified to accept an FVC in which a volume change of <40 ml in a 2 second period was not required provided that the forced expiratory time exceeded 12 seconds. Each spirometric recording was reviewed centrally and the percentage of tests meeting the external quality control criteria was fed back to the study centre to ensure high quality data throughout the study. Patients were asked to omit short acting inhaled bronchodilators for 4 hours before attendance, and long acting oral and inhaled agents for 12 hours. If the patient experienced a respiratory tract infection or exacerbation of COPD requiring treatment in the 4 weeks before their clinic visit, this was re-scheduled to provide valid spirometric testing.

Smoking status was assessed using exhaled breath carbon monoxide (CO) measured after a 20 second breath hold using a mini Smokerlyzer (Bedfont Technical Instruments Ltd, Kent, UK). Urinary cotinine was measured by thiocyanate assay in all patients during the run-in and subsequently in patients who claimed not to be smoking but had an expired CO level of >8 ppm. Self declared non-smokers were classified as smokers if their urinary cotinine concentration was >40 mg/ml and expired CO was >10 ppm or if the urinary cotinine value was missing but the expired CO was >10 ppm on more than two visits.

Atopic status was assessed objectively by skin prick testing to four common allergens (*Aspergillus fumigatus*, *Dermatophagoides pteronyssinus*, cat dander, and mixed grass pollen) together with a positive and negative control. Individuals were considered to be atopic if they reacted with a wheal of more than 3 mm in diameter to more than one of these allergens. Testing for atopy was conducted at the time of the first attendance.

### Study protocol

Patients attended on three occasions at 4 weekly intervals before treatment randomisation. On the first occasion (V0)



**Figure 1** Mean (SE) FEV<sub>1</sub> before and after salbutamol, ipratropium, and the combination on three occasions at monthly intervals. Note the differences in pre-bronchodilator values between visits and the lack of change in post-bronchodilator FEV<sub>1</sub> after the combination at visits 1 and 2.

they performed spirometric tests, then received 400 µg salbutamol via a large volume spacer (Volumatic) and spirometric tests were repeated after 30 minutes. Ipratropium bromide 80 µg was then given via the spacer and spirometric tests were repeated 30 minutes later. At the next attendance (V1) the order of the drugs was reversed, while on the third visit (V2) salbutamol inhalation was immediately followed by ipratropium and spirometric testing at 30 minutes. After V2, patients were randomised to receive either fluticasone 500 µg twice daily via the spacer or an identical placebo. They attended 3 monthly for repeat spirometric testing as described at V2 until 3 years of follow up had been completed or they had withdrawn from the study.

### Data analysis and statistical methods


The change in spirometric values after bronchodilation were expressed as: (a) absolute change (ml); (b) percentage change from baseline; and (c) change in percentage predicted normal values. Spirometric values for the normal population used the ECCS formulae.<sup>13</sup>

Student's *t* tests were used to test differences from baseline and differences in mean values between visits. FEV<sub>1</sub> repeatability was measured using the intraclass correlation coefficient. The relationship between pre-bronchodilator values and bronchodilator response was estimated using regression coefficients.<sup>19</sup> Interactions with smoking status, sex, and atopy were investigated using analyses of covariance. The rate of decline in FEV<sub>1</sub> was derived using the placebo data set only and was expressed as the change in post-bronchodilator FEV<sub>1</sub> (ml) per year. These data were analysed using a random coefficients mixed effects model as described by Burge *et al.*<sup>17</sup> Similarly, data for the change in health status with time and the exacerbation rate were collected and analysed as described in detail by Burge *et al.*<sup>17</sup> All tests were two sided with a 5% level of significance. Data are expressed as mean (SE) unless otherwise stated.


## RESULTS

### Study population

Of the 990 patients fulfilling the entry criteria, 751 completed the 2 month run-in and were randomised, 375 receiving placebo. Of the randomised population, 54% had used regular inhaled corticosteroids before the study. Complete data at all three bronchodilator assessments were available for 660 patients. The loss of data in the remaining 91 patients was largely due to delayed assessment because of respiratory tract



**Figure 2** Histograms of the distribution of bronchodilator response seen in data derived at visit 0 after salbutamol alone.




**Figure 3** Data at the same visit as fig 2 but after salbutamol and ipratropium and expressed as (A) percentage of predicted FEV<sub>1</sub>, (B) absolute change in FEV<sub>1</sub>, and (C) percentage change from baseline.

infections; these patients did not differ significantly in any baseline characteristic or prior treatment from those who are reported here. Details of the study population are presented in table 1 based on measurements made at V0.

#### Response to bronchodilator drugs


FEV<sub>1</sub> and FVC both increased significantly after inhaled salbutamol at V0 (mean change in FEV<sub>1</sub> 128 (4) ml, mean change



**Figure 4** Relationship between the response to bronchodilator and the pre-bronchodilator FEV<sub>1</sub> at visit 2. (A) Absolute change in FEV<sub>1</sub> is unrelated to initial FEV<sub>1</sub>. (B) Change as a percentage of baseline FEV<sub>1</sub> is related to initial FEV<sub>1</sub> in a curvilinear fashion which persisted even when the ATS absolute volume criteria were included (C).

in FVC 286 (12) ml). A further significant increase in both variables occurred after ipratropium (fig 1). The pre-bronchodilator FEV<sub>1</sub> at V1 was lower than at V0 ( $p < 0.0001$ ), and the increase in FEV<sub>1</sub> after ipratropium (the first drug given at V1) was larger than when salbutamol was given first at V0. The change in FEV<sub>1</sub> when ipratropium was added to salbutamol at V0 was 63 (4) ml, and the change when salbutamol was added to ipratropium at V1 was 39 (4) ml (difference 24 ml,  $p < 0.0001$ ). There were no significant differences in the mean post-bronchodilator FEV<sub>1</sub> between V1 and V2 or in the mean bronchodilator response at any visit. The intraclass correlation coefficient for pre-bronchodilator FEV<sub>1</sub> was 0.91 and for post-bronchodilator FEV<sub>1</sub> was 0.93 for the three visits.

The distribution of the change in FEV<sub>1</sub> expressed as a percentage of predicted after salbutamol was censored by our inclusion criteria (fig 2). The distribution became more obviously normal when data after both salbutamol and ipratropium were plotted (fig 3A). Similar patterns were seen when the absolute change in FEV<sub>1</sub> and percentage change from baseline were used, although the latter group were skewed towards apparent responsiveness (fig 3B and C).



**Figure 5** Changes in responder classification and corresponding subgroup mean FEV<sub>1</sub> at each visit after both bronchodilators using (A) American Thoracic Society and (B) European Respiratory Society criteria. Numbers in circles refer to the total classified as positive responders at that visit and those in squares are the non-responders on the same occasion. Note that some patients in the ERS criteria group exhibited a "response" after both drugs at the first visit despite being classified as non-responsive to salbutamol alone.

### Influence of baseline FEV<sub>1</sub> on likelihood of being classified as responsive

The relationships between the pre-bronchodilator FEV<sub>1</sub> and the size of the bronchodilator response expressed in different ways are shown in fig 4 using data from V2. The change in FEV<sub>1</sub>, whether expressed as an absolute value or as a percentage of predicted, was uninfluenced by the pre-bronchodilator FEV<sub>1</sub> when measured in absolute units. When the data were expressed as a percentage change from baseline there was a clear curvilinear relationship with the pre-bronchodilator FEV<sub>1</sub>, best described using a power function ( $r=0.17$ ,  $p<0.0001$ ). This relationship persisted ( $r=0.44$ ,  $p<0.0001$ ) even when patients whose FEV<sub>1</sub> changed by less than 200 ml were excluded (fig 4C).

### Reproducibility of the response

The reliability of the patient's responder classification is shown in fig 5 using data obtained following both bronchodilator drugs. Using the ATS classification, only 103/275 (37%) of those initially classified as reversible remained so on the two subsequent visits while 213/385 (55%) of those classified as irreversible showed equally inconsistent results. Comparable figures for the ERS classification were 32/149

(21%) initially classified as reversible and 375/511 (73%) as irreversible. Overall, 52% of patients classified by ATS criteria and 253/660 (38%) classified using ERS criteria would be reclassified if tested on a different occasion. There was a significant association ( $p<0.0001$ ) between the change in pre-bronchodilator FEV<sub>1</sub> between visits and the change in response classification—that is, an increase in pre-bronchodilator FEV<sub>1</sub> between visits was likely to be associated with reclassification to being irreversible and, conversely, a fall in pre-bronchodilator FEV<sub>1</sub> between visits led to reclassification as reversible. Patients identified as being consistently reversible by ATS and ERS classifications are compared in table 2. There were no significant differences between these groups in the numbers of smokers and atopic subjects.

Using data obtained at V2 following both bronchodilators, the absolute change in FEV<sub>1</sub> was unrelated to smoking status or atopy. There were no sex differences in the magnitude of response to bronchodilators. In this study 53% of the population had inhaled corticosteroids withdrawn at screening but there was no difference in the change in FEV<sub>1</sub> at V2 between these patients and those who had not previously received inhaled corticosteroids.

**Table 2** Demographic characteristics of patients consistently reversible and irreversible using ATS and ERS criteria

	ATS response (n=103)	ATS no response (n=213)	Difference (p value)	ERS response (n=32)	ERS no response (n=375)	Difference (p value)
Post-bronchodilator FEV <sub>1</sub> (l)	1.60 (0.04)	1.35 (0.03)	<0.0001	1.70 (0.07)	1.37 (0.02)	<0.0001
Change in FEV <sub>1</sub> (l)	0.34 (0.01)	0.09 (0.01)		0.37 (0.02)	0.13 (0.01)	
Change in FEV <sub>1</sub> (% predicted)	11.17 (0.29)	3.60 (0.21)		13.13 (0.48)	4.60 (0.17)	
% women	12	38	<0.0001	25	24	0.9
% smokers	48	47	>0.9	47	48	0.9
% atopic	32	24	0.1	28	24	0.6
% previous regular ICS	61	51	0.1	66	51	0.1

Values are mean (SE).

FEV<sub>1</sub>=forced expiratory volume in 1 second; ICS=inhaled corticosteroids.



### Bronchodilator response as a predictor of subsequent disease progression

The mean rate of decline in FEV<sub>1</sub> in placebo treated patients was 53 ml per year. We found no relationship between the absolute or percentage predicted changes in FEV<sub>1</sub> after bronchodilator and the subsequent rate of decline in FEV<sub>1</sub> in our model which controlled for the baseline post-bronchodilator data. The mean rate of decline in health status was unrelated to baseline bronchodilator response ( $p=0.4$ ). Bronchodilator response was divided into responders and non-responders by the median value (170 ml). Decline in health status was not significantly different between the two groups (responders 2.8 units/year; non-responders 3.4 units/year;  $p=0.3$ ). The annual rate of exacerbations was not significantly different between the two groups (responders 1.5 exacerbations/year; non-responders 1.5 exacerbations/year;  $p=0.6$ ).

### DISCUSSION

COPD is now defined using the combination of a clinical history and objective evidence of airflow limitation. Data from this study show that these criteria identify patients with an accelerated rate of decline in FEV<sub>1</sub>. However, the distinction from chronic asthma with limited reversibility remains difficult, and most treatment guidelines use the spirometric response to a bronchodilator drug to aid the diagnosis and, in some cases, to make recommendations about treatment decisions.<sup>12</sup> Previous studies have examined the ability of bronchodilator testing to differentiate between asthma and COPD in milder disease and have found no clear distinction spirometrically between the two.<sup>9, 20</sup> This has not prevented these criteria being widely recommended in the assessment of more severe COPD or in the selection of patients for inclusion in treatment trials.<sup>17, 21</sup> In this study we examined the reliability of the bronchodilator response in moderate to severe COPD defined as "poorly reversible" disease by one set of criteria and have related it to clinically relevant outcomes. Our data suggest that the current definitions of bronchodilator reversibility have significant limitations in established COPD and may be potentially misleading.

As in the EUROSCOP trial,<sup>22</sup> we selected patients with a <10% change in predicted FEV<sub>1</sub> after an inhaled  $\beta$  agonist. The distribution of bronchodilator responses using this criterion was censored but returned towards normal once the second bronchodilator drug was added. In these patients we could not identify a separate population of more responsive patients however the data were expressed.

Using a second drug, whether ipratropium or salbutamol, increased the mean FEV<sub>1</sub> and changed the number of patients classified as reversible. The group mean change in FEV<sub>1</sub> after each drug was reproducible between visits despite the significant fall in pre-bronchodilator FEV<sub>1</sub> which was probably related to both the withdrawal of inhaled corticosteroids and regression to the mean.<sup>23</sup> The post-bronchodilator FEV<sub>1</sub> values were highly correlated between visits, supporting the use of this measurement as the principal outcome in longitudinal studies of the evolution of the disease.

Neither the American nor European definitions were acceptably reproducible. Over half the patients initially classified as reversible by the ATS/GOLD definition would be reclassified had they attended on another occasion. Likewise, 38% of those classified by the European criteria changed their apparent responder status with time, despite all being irreversible to salbutamol alone at the first visit.

A further problem with the ATS and GOLD definitions, but not with those based on an absolute or percentage predicted change, is their dependence on the baseline FEV<sub>1</sub> even when an initial absolute value of 200 ml is considered a threshold for this measurement (fig 4C). This may suggest that a substantial degree of reversibility is present even when the absolute

increase in FEV<sub>1</sub> is similar to that seen in less severe disease. The absolute changes in FEV<sub>1</sub> we saw were similar to that in much milder disease in the Lung Health Study.<sup>18</sup>

Our data were uninfluenced by differences in sex, current smoking status, atopic status, or the prior use of inhaled corticosteroids. Neither smoking status nor atopy were over-represented in the patients who showed the most "consistent" positive responses, suggesting that improvement in lung function in COPD does not correspond to either an asthmatic or ex-smoking phenotype. Patients treated previously with inhaled corticosteroids did not differ in their bronchodilator responses from those not so treated. The most likely explanation for the between day variation in classification is the effect of small fluctuations in bronchomotor tone as shown by the inverse relationship between pre-bronchodilator FEV<sub>1</sub> and the chance of a change in responder classification. Similar fluctuations in airway calibre have been noted in other COPD populations and have been related to the degree of cholinergic tone in the airway smooth muscle.<sup>6, 24</sup>

Our model of the rate of decline in FEV<sub>1</sub> controlled for the post-bronchodilator FEV<sub>1</sub> value obtained during the run-in period. We found no evidence for a relationship between the change in FEV<sub>1</sub> after bronchodilators, however expressed, and the rate of decline in lung function. We confined our analysis to the placebo treated patients to exclude any confounding effects of the inhaled corticosteroids. Our data contrast with those obtained from a more mixed population where only partial analysis of the FEV<sub>1</sub> decline was available.<sup>7</sup> It emphasises the difficulty of using measures like a bronchodilator "response" in patients with more severe and structurally determined airflow limitation. Our results are in keeping with a long term Danish population study where COPD mortality was related to both pre-bronchodilator FEV<sub>1</sub> and the change in FEV<sub>1</sub> at study entry, but the latter variable was no longer significant when the relationship was expressed in terms of the post-bronchodilator value.<sup>25</sup> The failure of the response to predict future changes in health status or exacerbation frequency is not surprising given the limitations of this measurement.

We could not, for logistic reasons, include a group receiving placebo inhalations but felt that the reproducibility of the FEV<sub>1</sub> which this assesses has been reported sufficiently frequently to make this unnecessary.<sup>10, 13</sup> The doses of the bronchodilator drugs may not have been maximal<sup>26, 27</sup> or optimally timed, but these minor differences are unlikely to have systematically affected our results. This study specifically addressed the usefulness of classifying patients who are believed to have COPD on their response to one dose of one bronchodilator, a common clinical situation. The conclusion that this is a continuously distributed response susceptible to the number of drugs used and day of testing suggests that, even in this group of patients, identifying responder status in this way is of little practical value. We cannot address whether this would be true for those with a more substantial bronchodilator response, but the variability in the tail of our response distribution suggests that it may also be true in these cases.

Our data are not surprising given the day to day variation in bronchomotor tone and the arbitrary nature of the definitions adopted. Unfortunately, many clinicians still rely on these responses to decide whether patients have COPD and what treatment they should receive, while regulators in Europe and North America take very different views about the inclusion of reversibility data in clinical treatment trials. A major purpose of this study has been to alert them and the regulatory authorities to the significant limitation of any classification currently in use. This variability in classification helps to explain the unreliability of bronchodilator responsiveness as a predictor of improvement after treatment.<sup>28, 29</sup> If bronchodilator response data are to be presented in COPD, then the absolute change in FEV<sub>1</sub> should be reported without making prior assumptions about its diagnostic significance.

## ACKNOWLEDGEMENTS

This study would not have been possible without the sustained efforts of a large number of people who are listed in detail in the appendix to reference 18. Particular mention is due to Dr John Poundsford for his help in the early stages of data evaluation and to Ms Lisa Willits for her significant contribution to the statistical analysis of these data.

.....

### Authors' affiliations

**P M A Calverley**, Department of Medicine, The University of Liverpool, Liverpool, UK

**P S Burge**, Birmingham Heartlands Hospital, Birmingham, UK

**S Spencer, P W Jones**, St George's Hospital Medical School, London, UK

**J A Anderson**, Department of Medical Statistics, GlaxoSmithKline R&D, UK

This study was supported by a research grant from GlaxoSmithKline plc.

## REFERENCES

- American Thoracic Society.** Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1995;**152**:S77-120.
- Siafakas NM, Vermeire P, Pride NB, et al.** Optimal assessment and management of chronic obstructive pulmonary disease (COPD). *Eur Respir J* 1995;**8**:1398-420.
- COPD Guidelines Group of the Standards of Care Committee of the BTS.** BTS guidelines for the management of chronic obstructive pulmonary disease. *Thorax* 1997;**52**(Suppl 5):S1-28.
- Callahan CM, Diittus RS, Katz BP.** Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease. A meta-analysis. *Ann Intern Med* 1991;**114**:216-23.
- Davies L, Nisar M, Pearson MG, et al.** Oral corticosteroid trials in the management of stable chronic obstructive pulmonary disease. *Q J Med* 1999;**92**:395-400.
- Nisar M, Earis JE, Pearson MG, et al.** Acute bronchodilator trials in chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1992;**146**:555-9.
- Anthonisen NR, Wright EC, Hodgkin JE.** Prognosis in chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1986;**133**:14-20.
- Kerstjens HA, Brand PL, Postma DS.** Risk factors for accelerated decline among patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1996;**154**:S266-72.
- Brand PL, Quanjer PH, Postma DS, et al.** Interpretation of bronchodilator response in patients with obstructive airways disease. The Dutch Chronic Non-Specific Lung Disease (CNSLD) Study Group. *Thorax* 1992;**47**:429-36.
- Tweeddale PM, Alexander F, McHardy GJ.** Short term variability in FEV<sub>1</sub> and bronchodilator responsiveness in patients with obstructive ventilatory defects. *Thorax* 1987;**42**:487-90.
- American Thoracic Society.** ATS standardization of spirometry: 1994 update. *Am J Respir Crit Care Med* 1994;**150**:1107-36.
- Pauwels RA, Buist AS, Calverley PMA, et al.** Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2001;**163**:1256-76.
- Quanjer PH, Tammeling GJ, Cotes JE, et al.** Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. *Eur Respir J Suppl* 1993;**16**:5-40.
- Weir DC, Gove RI, Robertson AS, et al.** Corticosteroid trials in non-asthmatic chronic airflow obstruction: a comparison of oral prednisolone and inhaled beclomethasone dipropionate. *Thorax* 1990;**45**:112-7.
- Anthonisen NR, Wright EC.** Bronchodilator response in chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1986;**133**:814-9.
- Kerstjens HA, Overbeek SE, Schouten JP, et al.** Airways hyperresponsiveness, bronchodilator response, allergy and smoking predict improvement in FEV<sub>1</sub> during long-term inhaled corticosteroid treatment. Dutch CNSLD Study Group. *Eur Respir J* 1993;**6**:868-76.
- Burge PS, Calverley PM, Jones PW, et al.** Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. *BMJ* 2000;**320**:1297-303.
- Enright PL, Johnson LR, Connett JE, et al.** Spirometry in the Lung Health Study. 1. Methods and quality control. *Am Rev Respir Dis* 1991;**143**:1215-23.
- Bland M.** *An introduction to medical statistics.* Oxford: Oxford Medical Publications, 1987.
- Dompeling E, Van Schayck CP, Molema J, et al.** A comparison of six different ways of expressing the bronchodilating response in asthma and COPD: reproducibility and dependence of prebronchodilator FEV<sub>1</sub>. *Eur Respir J* 1992;**5**:975-81.
- Lofdahl CG, Postma DS, Laitinen LA, et al.** The European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): recruitment methods and strategies. *Respir Med* 1998;**92**:467-72.
- Pauwels RA, Lofdahl C-G, Laitinen LA, et al.** Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. *N Engl J Med* 1999;**340**:1948-53.
- Jarad NA, Wedzicha JA, Burge PS, et al.** An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. *Respir Med* 1999;**93**:161-8.
- Gross NJ, Co E, Skorodin MS.** Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects. *Chest* 1989;**96**:984-7.
- Hansen EF, Phanareth K, Laursen LC, et al.** Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1999;**159**:1267-71.
- Vathenen AS, Britton JR, Ebdon P, et al.** High-dose inhaled albuterol in severe chronic airflow limitation. *Am Rev Respir Dis* 1988;**138**:850-5.
- Gross NJ, Petty TL, Friedman M, et al.** Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease. A three-center study. *Am Rev Respir Dis* 1989;**139**:1188-91.
- Hay JG, Stone P, Carter J, et al.** Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. *Eur Respir J* 1992;**5**:659-64.
- Jones PW, Bosh TK.** Quality of life changes in COPD patients treated with salmeterol. *Am J Respir Crit Care Med* 1997;**155**:1283-9.